NeuroTrauma Sciences LLC
  • What We Do
  • Our Team
  • Our Investors
  • News
  • Events
  • Contact
Select Page

NeuroTrauma Sciences Appoints Dr. Todd Verdoorn as Vice President of Research and Development

Dec 18, 2019

FOR IMMEDIATE RELEASE (PDF DOWNLOAD) -NeuroTrauma Sciences Appoints Dr. Todd Verdoorn as Vice President of Research and Development ATLANTA, Ga., December 18, 2019 – NeuroTrauma Sciences, LLC (NTS), a biopharmaceutical company, today announced the...

read more

NeuroTrauma Sciences Enters Into Worldwide License Agreement with Emory University for Molecules to Treat Stroke and Traumatic Brain Injury

Dec 11, 2019

FOR IMMEDIATE RELEASE (PDF DOWNLOAD) -NTS Exercises Option after Conducting Preclinical Research on Neuroactive Small Molecule ATLANTA, Ga., December 11, 2019 – – NeuroTrauma Sciences, LLC (NTS), a biopharmaceutical company, and Emory University (Emory), a...

read more

NeurExo Sciences and Henry Ford Health System Present Preclinical Data on Exosomes at ISEV2019 Annual Meeting

Apr 26, 2019

FOR IMMEDIATE RELEASE (PDF DOWNLOAD) Exosomes demonstrate ability to enhance anti-tumor effect of platinum-based drugs and to ameliorate peripheral neuropathy ATLANTA and DETROIT, April 26, 2019 – NeurExo Sciences, LLC (NXS), a biotechnology company...

read more

NeurExo Sciences and Henry Ford Health System Announce Upcoming Presentations on Exosomes at ISEV2019 Annual Meeting

Apr 23, 2019

FOR IMMEDIATE RELEASE ATLANTA and DETROIT, April 22, 2019 – NeurExo Sciences, LLC (NXS), a subsidiary of NeuroTrauma Sciences, LLC, and biotechnology company focused on the development of exosome therapies, and Henry Ford Health System (HFHS), a non-profit...

read more

NeurExo Sciences and Henry Ford Health System Announce Upcoming Presentations on Exosomes in Stroke at 45th International Stroke Conference February 6-8

Jan 31, 2019

Dr. Michael Chopp to Highlight Advances in Stroke at Exosome Teach-In Event in New York on February 12th ATLANTA, DETROIT and HONOLULU, January 31, 2019 – NeurExo Sciences, LLC (NXS), a biotechnology company focused on the development of exosome therapies,...

read more

NeurExo Sciences to Host Teach-in Featuring Michael Chopp, PhD and Pioneering Exosome Technology

Jan 23, 2019

Research indicates exosomes have therapeutic potential for improving recovery after stroke, traumatic brain injury ATLANTA and DETROIT, January 23, 2019 – NeurExo Sciences, LLC (NXS), a biopharmaceutical company and subsidiary of NeuroTrauma Sciences, LLC, will be...

read more

NeuroTrauma Sciences and Henry Ford Health System Announce Research and License Agreements to Develop Exosome Technology for Neurological Injury

Jul 16, 2018

Research indicates exosomes have therapeutic potential for improving recovery after stroke, traumatic brain injury   ATLANTA and DETROIT, July 16, 2018 – NeuroTrauma Sciences, LLC (NTS), a biopharmaceutical company, and Henry Ford Health System, a...

read more
© 2021 NeuroTrauma Sciences, LLC.